Duyuru • Apr 24
Talius Group Limited, Annual General Meeting, May 28, 2026 Talius Group Limited, Annual General Meeting, May 28, 2026. Location: physically at the offices of bdo, level 18, 360 queen street, brisbane, qld 4000 Australia New Risk • Feb 24
New major risk - Revenue and earnings growth Earnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.1% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (AU$23.9m market cap, or US$16.9m). Reported Earnings • Feb 24
Full year 2025 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in FY 2024) Full year 2025 results: AU$0.005 loss per share. Revenue: AU$7.72m (down 31% from FY 2024). Net loss: AU$1.46m (loss narrowed 55% from FY 2024). Board Change • Feb 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Greg Kennish was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Nov 27
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$27.2m market cap, or US$17.8m). Duyuru • Nov 08
Talius Group Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million. Talius Group Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Transaction Features: Subsequent Direct Listing Duyuru • Oct 27
Talius Group Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million. Talius Group Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Transaction Features: Subsequent Direct Listing Reported Earnings • Aug 28
First half 2025 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2024) First half 2025 results: EPS: AU$0 (improved from AU$0.001 loss in 1H 2024). Revenue: AU$4.83m (up 28% from 1H 2024). Net loss: AU$626.2k (loss narrowed 63% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. New Risk • Jun 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$2.29m (US$1.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (AU$2.29m market cap, or US$1.48m). Duyuru • Apr 03
Talius Group Limited, Annual General Meeting, May 22, 2025 Talius Group Limited, Annual General Meeting, May 22, 2025. Location: at the office of bdo, level 10, 12 creek steet, brisbane Australia Duyuru • Apr 02
Talius Group Limited Announces Board and Committee Changes Talius Group Limited announced some key changes to the Board of Directors to ensure a strong and aligned composition for the future growth of the Company. Mr. Stephen Norris has been appointed to the Board as a Non-Executive Director. Mr. Norris has vast experience in the Aged Care Sector and has aligned interests in the success of Talius, given his recent strategic investment in December 2024. The company announced the appointment of Mr. Greg Kennish as a Non-Executive Director. Mr. Kennish brings a wealth of international experience and a deep understanding of technology platforms, including (but not limited to) SaaS models. Mr. Kennish has previously cofounded and led software companies in Asia and Australia, including an ASX listed technology provider. Mr. Kennish will also be appointed as Chair of the Audit & Risk Committee. The Company announced that Mr. Leylan Neep has decided to step down from his role as Director and Chair of the Board, effective immediately. Mr. Ramsay Carter, Non-Executive Director, has agreed to take up the Board Chair role with immediate effect and will also Chair the Nomination & Remuneration Committee. Mr. Neep has served as Chair since September 2020 and overseen the repositioning of Talius from its legacy Homestay Care to its current position as a leading provider of technology-enabled solutions. The Board expresses its gratitude to Mr. Neep for his commitment and stewardship during his tenure as Chair. Mr. Carter has been a Non-Executive Director of the Company since June 2020 and has been a key driver of Talius’ governance and strategy during that time. His knowledge of the Company, the Executive and shareholders provides for a seamless transition of the Chair role. Reported Earnings • Feb 28
Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2023) Full year 2024 results: AU$0.001 loss per share (in line with FY 2023). Revenue: AU$11.4m (down 6.6% from FY 2023). Net loss: AU$3.22m (loss widened 140% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 16% per year. Duyuru • Jan 29
Talius Group Limited Announces Resignation of Marguerite Frances Haertsch as Executive Director, Effective 28 January 2025 Talius Group Limited advised that Dr. Marguerite Frances Haertsch has resigned from her role as Executive Director of the Company to pursue other opportunities. Dr. Haertsch was initially engaged as a consultant in April 2023 to assist Talius in advancing its strategic initiatives and was subsequently appointed as Executive Director of the Company on 15 August 2024. Date of last notice is 17 January 2025. Date that director ceased to be director is 28 January 2025. Duyuru • Dec 31
Talius Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.57445 million. Talius Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.57445 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 286,050,000
Price\Range: AUD 0.009
Transaction Features: Subsequent Direct Listing Duyuru • Dec 25
Talius Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.57445 million. Talius Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.57445 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 286,050,000
Price\Range: AUD 0.009
Transaction Features: Subsequent Direct Listing New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (AU$18.0m market cap, or US$12.2m). Duyuru • Aug 15
Talius Group Limited Appoints Dr. Maggie Haertsch as Executive Director Talius Group Limited announced the appointment of Dr. Maggie Haertsch to its Board of Directors as an Executive Director, effective immediately. Dr. Haertsch, a seasoned expert in the aged care industry, has been with Talius since March 2023, serving as the Consulting Clinical Research Director. During her tenure, she has been instrumental in advancing Talius' strategic initiatives, including forging alliances with industry bodies, successfully managing the ARIIA Grant project, and refining the Company's strategy across the residential aged care and home care sectors. In her new role, Dr. Haertsch will continue to report to Managing Director Graham Russell while expanding her responsibilities within the Board. With over 40 years of experience in the health and aged care sectors, both in Australia and internationally, Dr. Haertsch brings a wealth of knowledge and a diverse skill set to the Talius Board. Her extensive career spans clinical practice in tertiary teaching hospitals, acute care services, community settings, and low-tech environments, complemented by significant leadership roles in research, education, and executive management. Dr. Haertsch is exceptionally qualified to contribute to Talius' mission in the aged care sector. She holds a PhD in Behavioral Sciences in Medicine, has completed the Leadership in Digital Transformation in Healthcare program at Harvard Medical School, and possesses a Post-Graduate Diploma in Health Science (Primary Health Care) from the Faculty of Health Sciences from the University of Newcastle. In addition, she is a Registered Nurse and was previously a Registered Midwife. Duyuru • Apr 03
Talius Group Limited, Annual General Meeting, May 23, 2024 Talius Group Limited, Annual General Meeting, May 23, 2024, at 10:30 E. Australia Standard Time. New Risk • Mar 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (AU$23.2m market cap, or US$15.3m). Reported Earnings • Feb 29
Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022) Full year 2023 results: AU$0.001 loss per share (in line with FY 2022). Revenue: AU$12.4m (up 73% from FY 2022). Net loss: AU$1.34m (loss narrowed 17% from FY 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Duyuru • Dec 08
Talius Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Talius Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 277,777,778
Price\Range: AUD 0.009
Transaction Features: Subsequent Direct Listing Reported Earnings • Sep 02
First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022) First half 2023 results: EPS: AU$0 (in line with 1H 2022). Revenue: AU$6.17m (up 179% from 1H 2022). Net loss: AU$290.0k (loss narrowed 49% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 01
Non-Executive Director recently bought AU$55k worth of stock On the 30th of August, Ramsay Carter bought around 500k shares on-market at roughly AU$0.11 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$130k more in shares than they have sold in the last 12 months. New Risk • Jul 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Revenue is less than US$5m (AU$7.2m revenue, or US$4.8m). Market cap is less than US$100m (AU$27.3m market cap, or US$18.3m). Reported Earnings • Mar 03
Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021) Full year 2022 results: AU$0.001 loss per share (in line with FY 2021). Revenue: AU$7.20m (up 99% from FY 2021). Net loss: AU$1.62m (loss narrowed 21% from FY 2021). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). MD & Director Graham Russell is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Jun 07
Non-Executive Director recently bought AU$60k worth of stock On the 1st of June, Ramsay Carter bought around 5m shares on-market at roughly AU$0.012 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$864k more in shares than they have sold in the last 12 months. Duyuru • May 09
Hsc Technology Group Ltd Secures Therapeutic Goods Approval for CardiacSense HSC Technology Group Ltd. announced Therapeutic Goods Approval1 (TGA) and the beginning of commercialisation of the CardiacSense solution. The CardiacSense solution is a watch which has been developed from the ground up as an enterprise grade medical device for continuous measurement of heart rate and arrhythmias at ECG-level accuracy. The medical indications certified include "detection of Atrial Fibrillation (A-Fib), and monitoring of Heart Rate Variability (HRV), with continuous Photoplethysmography (PPG) and spot Electrocardiogram (ECG). HSC Technology Group is the exclusive partner with CardiacSense in Australia and New Zealand following an extensive development process and clinical trials. HSC is the first and only company to receive TGA certification for continuous PPG wristband monitoring at the individual heartbeat level and arrhythmia detection, a milestone that will enable HSC to provide proactive health monitoring to the Australian and New Zealand market. HSC Technology Group has integrated the Cardiac Sense data into the HSC Talius Platform to enable emergency response and remote patient monitoring, providing a key element for an end to end solution of 24hr support. HSC sees this new offering as a continuation of the Talius IoT data collection processing and the entry of HSC into the healthcare industry. Board Change • Apr 27
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). MD & Director Graham Russell is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Mar 01
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: AU$0 (down 100% from FY 2020). Net loss: AU$2.07m (loss narrowed 13% from FY 2020). Profit margin: (up from net loss in FY 2020). The move to profitability was driven by lower revenue. Revenue was in line with analyst estimates. Recent Insider Transactions • Oct 22
Insider recently bought AU$714k worth of stock On the 19th of October, Kyle Haynes bought around 42m shares on-market at roughly AU$0.017 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$791k more in shares than they have sold in the last 12 months. Recent Insider Transactions • May 08
Non-Executive Chairman recently bought AU$51k worth of stock On the 7th of May, Leylan Neep bought around 3m shares on-market at roughly AU$0.017 per share. This was the largest purchase by an insider in the last 3 months. This was Leylan's only on-market trade for the last 12 months. Executive Departure • Apr 27
CFO & Joint Company Secretary has left the company On the 19th of April, Marcus Fraumano's tenure in the role of CFO & Joint Company Secretary ended. We don't have any record of a personal shareholding under Marcus' name. A total of 4 executives have left over the last 12 months. Duyuru • Mar 09
Hsc Technology Group Ltd Announces it is Partnering with Multinational Johnson Controls' ADT Security Business to Supply Next Generation Assistive Technology Solutions to Their Australian Client Base HSC Technology Group Ltd. announced it is partnering with multinational Johnson Controls' ADT Security business to supply next generation assistive technology solutions to their Australian client base. Johnson Controls offers the world's portfolio of building products, technologies, software and services. The ADT brand is synonymous globally as a security and safety company providing ongoing reliable, quality service and innovative products to all clients. ADT recognised the need to replace their Personal Emergency Response System (PERS) platform, which is built on ageing 3G communications technology. After a comprehensive due diligence process, ADT selected HSC and its solution based on the advanced suite of hardware and the TALIUS IoT platform. The HSC solution will enable future sales opportunities for ADT to its extensive client base while significantly improving the clients' safety and independence. Duyuru • Mar 05
HSC Technology Group Ltd Receives Additional Order from ACH Group HSC Technology Group Ltd. announced that the Company has received further purchase orders for approximately $618,000, from the Aged Care & Housing Group Inc, relating to a further two sites of residential care in South Australia. As previously announced on 28 January 2020, HSC was awarded a tender to provide assistive technology to multiple ACH Group sites in South Australia. The ACH Group tender sought a solution targeting efficiency and optimization through the use of IoT technology, across its residential aged care sites, which currently includes more than 800 residents collectively. The assistive technology scope includes nurse call tracking, real time location systems, and the TALIUS IoT solution. Reported Earnings • Feb 28
Full year 2020 earnings released: AU$0.001 loss per share (vs AU$0.005 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: AU$3.11m (up 170% from FY 2019). Net loss: AU$2.37m (loss narrowed 46% from FY 2019). Duyuru • Dec 25
HSC Technology Group Ltd announced that it has received AUD 2.998 million in funding On December 24, 2020, HSC Technology Group Ltd (ASX:HSC) closed the transaction. The company issued 176,352,940 shares for the gross proceeds of AUD 2,997,999.98. Duyuru • Dec 23
HSC Technology Group Ltd announced that it expects to receive AUD 3 million in funding HSC Technology Group Ltd (ASX:HSC) announced a private placement of 176,470,588 common shares at a price of AUD 0.017 per share for gross proceeds of AUD 2,999,999.996 on December 21, 2020. The transaction will include participation from institutional and sophisticated investors. The company expects to close the transaction on December 24, 2020. Duyuru • Nov 05
HSC Technology Group Ltd Announces New Executive Appointments HSC Technology Group Ltd. announced it has appointed two international finance and healthcare industry executives to its Advisory Board to assist in the growth of the Company and improve its value and performance. Eugene Lim and Martin Robinson will take up the roles after HSC determined to implement a number of operational and other enhancements, including the establishment of the Advisory Board. Mr. Lim is a former Managing Director at Credit Suisse (Asia) where he was employed for over 19 years including roles as CEO of Credit Suisse Securities Singapore, responsible for overseeing all equities securities business conducted in the country, and head of ASEAN Equity Sales, responsible for managing the equity distribution business in all ASEAN offices. His positions included being a conduit between Capital Markets and Corporate Finance teams on numerous transactions and public offerings in the region. For the past six years he has advised on private equity transactions in the Asia Pacific region for family offices and wealth management companies. Mr. Robinson has over 20 years of growth and private equity investing, C-suite, investment committee, corporate finance and legal experience including over USD 2 billion of healthcare investments/exits across Asia, Australia, Africa and the Middle East since 2010. He is a founding partner of HEAL Partners, a health, education and lifestyle growth stage private equity fund. He previously led the healthcare private equity strategy for a multi-billion dollar private investment group based in Singapore, originating and leading the USD 123 million acquisition of Hoan My Medical Corporation, and as Chairman, led the transformation of the group into Vietnam's leading hospital network. He also originated and led the Series A round investment into HaloDoc, Indonesia's leading health tech mobile platform and was a Board member. Mr. Robinson previously worked for the Religare/Fortis Healthcare Group in Singapore where he was responsible for several healthcare principal investments across Asia-Pacific including the acquisition of Quality Healthcare Hong Kong, Radlink Singapore and the takeover of Dental Corp. Australia. He also spent five years with Macquarie Bank (Australia & Hong Kong), where he was responsible for the Group's Asian principal investments and Head of Sponsor Coverage Asia. Duyuru • Sep 24
HSC Technology Group Ltd Wins Singapore Aged Care Facility Contract HSC Technology Group Limited announced it has been awarded a contract through its Singapore based partner for the HSC IoT marketplace to supply hardware and software solutions to the St John's Home for Elderly Persons. The contract includes an ecosystem of IOT solutions, including a next generation Nurse Call system which provides emergency response and geo-location data for each resident, staff member and asset; a Vital Signs Medical cart that allows care teams to take daily vital signs of each resident; and a RFID-based laundry management system that will streamline operations, improve efficiency and quality assurance, all utilising the HSC proprietary analytics software TALIUS. The Singapore Government's National Council of Social Services, who are a major sponsor of the tender, were provided a demonstration of the hardware and software before it was awarded.